NTP Update by unknown
NIEHS News
Fouts Retires
James R Fouts, a scientist who
has spent more than 40 years at _ as
the frontier ofthe development
of toxicology and environmen-
tal health as scientific disci-
plines, has retired as Senior
Scientific Advisor to the direc-
tor ofthe NIEHS. Fouts joined
the NIEHS as a senior scientist in 1970 and served until his
retirement on the institute's executive committee. "The science
that Dr. Fouts did here, the scientists that he trained here and
around the nation and the world, and his creative contributions
to programs will have a lasting impact for the future," said
NIEHS Director Kenneth Olden.
During his years of scientific research, Fouts's expansive
range of interests have included mammalian and marine drug-
metabolizing enzyme systems; comparative pharmacology and
drug metabolism; the pharmacology of antimetabolites and
antibiotics; drug-chemical interactions; preclinical drugtesting;
and pharmacogenetics. Fouts is 1 of 57 pharmacologists to be
named to the "1000 Contemporary Scientists Most-Cited
1965-1978," by Current Contents, an indication of the funda-
mental impact ofhis research to the research ofothers.
Fouts received abachelor's degreewith highest honors in chem-
istry at Northwestern University, where he was appointed a tutorial
fellowinbiochemistry. Heearnedhis doctorate in biochemistryand
pharmacology at Northwestern University and later worked at
Burroughs Wellcome Research Laboratories in Tuckahoe, New
York, under Nobel Laureate George Hitchings. In 1957, Fouts
joined the faculty of the Department of Pharmacology in the
College ofMedicine at the UniversityofIowa, where he also served
as directoroftheOakdaleToxicologyCenter.
A touchstone throughout his careerhas been Fouts's enthusi-
asm for training young scientists. Over the years he has trained
19 postdoctoral students and 17 graduate students, including
senior scientists at the NIEHS, and has served as an informal
mentorand teacher to manyothers.
ICt N tNTP Update
The National Toxicology
m Program presented eight techni-
'. O' cal reports at a public review by
*'* the NTP's Board of Scientific
Counselors on June 20-21 at the
NIEHS. These reports included a predictive
analysis ofpotential noncarcinogenicity based
on metabolism, six standard studies character-
izing the toxicology and carcinogenicity of
selected chemicals, and a comparison study of
the effects of limiting food consumption or
bodyweights on carcinogenesis evaluations.
1,4-Butanediol. The NCI nominated
1,4-butanediol for study because of its high
volume production as a chemical intermediate
and potential for worker exposure. 1,4-
Butanediol metabolizes rapidly to y-hydroxy-
butyric acid, which is also the end metabolite
of y-butyrolactone. Because the NTP has
already performed a full toxicology and car-
cinogenesis study of y-butyrolactone and
found no effects at anydoses, itwas possible to
predict that 1,4-butanediol would similarly
not becarcinogenic in animals.
Codeine. Codeine is used in a variety of
pharmaceuticals as an analgesic, sedative, and
antitussive agent and is one of the most fre-
quently prescribed therapeutic drugs in the
United States. In two-year studies, rats and
mice were given codeine in the feed at doses
ranging from 10 to 100 times the human pre-
scription doses (on a dose per body weight
basis). There was no evidence ofcarcinogenici-
tyofcodeine in thesestudies.
1,2-Dihydro-2,2,4-trimethylquinoline.
1,2-Dihydro-2,2,4-trimethylquinoline is used
in the preparation ofantioxidants for butadi-
ene-based rubbers and latexes. In two-year
studies, the chemical (in acetone solution) was
applied five times per week to the skin ofrats
and mice. Male rats exhibited an increased
incidence of kidney neoplasms, indicating
some evidence ofcarcinogenic activity. There
was no evidence ofcarcinogenicity in female
rats or in eithersexofmice.
Butyl benzylphthalate. Butyl benzyl
phthalate is used as a plasticizer in a variety of
synthetic polymers. In a mating study, expo-
sure to butyl benzyl phthalate in the feed for
10 weeks produced marked effects on male
reproductive parameters, including decreased
testis, epididymis, and seminiferous tubule
weights, and dramatically decreased sperm
production. In two-year studies, male rats
exhibited some evidence ofcarcinogenic activi-
ty based on an increase incidence ofneoplasms
ofthe pancreas. There was equivocal evidence
ofcarcinogenic activity in female rats based on
the occurrence ofa few uncommon neoplasms
in the pancreas and urinarybladder.
Salicylazosulfapyridine. Salicylazo-
sulfapyridine (SASP) is used in the treatment
ofulcerative colitis and Crohn's disease. When
given in the feed for two years, SASP caused
liver tumors in male and female mice, which
was interpreted as clear evidence of carcino-
genic activity. In rats, SASP caused the forma-
tion of calculi and proteinaceous concretions
in the urinary bladder, extensive urinary blad-
der hyperplasia, and some papillomas, which
were interpreted as some evidence ofcarcino-
genicactivity.
t-Butylhydroquinone. t-Butylhydro-
quinone is an antioxidant used in cosmetics
and meat products. It was not carcinogenic in
rats or mice when given in the feed for two
years.
Scopolamine hydrobromide tribydrate.
Scopolamine hydrobromide trihydrate is the
active ingredient in transdermal patches for
motion sickness and is also used in ophthalmic
preparations. It was not carcinogenic in rats or
mice when given in water by oral gavage for
two years.
Diet Restriction Studies
Studies of butyl benzyl phthalate, SASP, t-
butylhydroquinone, and scopolamine hydro-
bromide trihydrate each included additional
groups ofanimals that were used to compare
the standard NTP bioassay protocol, in
which animals are given access to feed ad
libitum, with protocols where the amount of
food consumed was restricted. Comparisons
were made between the tumor incidences in
animals exposed to chemical with their nor-
mal controls and with controls that had diets
restricted such that their body weights
matched the exposed animals. Other com-
parisons were made where control animals
and exposed animals received approximately
20% less feed than animals eating unrestrict-
ed amounts.
In general, animals with lower body
weights or those receiving less food had
lower incidences ofneoplasms at several sites.
The sensitivity of the bioassay to detect car-
cinogenic responses was affected by dietary
restriction: when dosed animals in the ad
libitum protocol were compared with con-
trols that had similar body weights, the sig-
nificance of the tumor incidences was
greater. However, some effects observed in
the normal ad libitum protocol were not
reproduced when control and dosed animals
were subject to dietary restriction. The rela-
tions between reduced body weights and
lower incidences ofneoplasms also illustrated
the importance ofdose selection in design of
long-term animal studies, in which doses
higher than the "minimally toxic dose"
might result in lower bodyweights and com-
plicate comparisons with concurrent control
groups.
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